Carfilzomib is a novel proteasome inhibitor utilized in the battle against cancer. It drug functions by blocking the activity of the proteasome, a cellular machine responsible for the destruction of proteins. By hampering this mechanism, carfilzomib results in the buildup of damaged or abnormal proteins, ultimately causing cell death. Carfilzomib e

Tepotinib, also known as {MSC2156119|the developmental compound|this drug), represents a promising advance in the management of NSCLC, particularly in patients harboring MET exon 14 alterations. This specific tyrosine kinase agent|TKI presents remarkable activity against cancer spread in laboratory tests and early-phase clinical trials. Its mechani

Teclistamab serves as a revolutionary novel anti-BCMA antibody drug compound, designated JNJ-64007957, featuring immense promise in the therapy of multiple myeloma. This innovative therapeutic works by specifically targeting BCMA, a molecule highly expressed on the surface of myeloma cells. Through this precise strategy, teclistamab delivers a pote